Akari Therapeutics, Plc: research and development expense
Research and development expense for Akari Therapeutics, Plc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Akari Therapeutics, Plc financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 2,815,000 | USD | 2026-03-30 | 10-K · 0001493152-26-013664 |
| 2024-01-01 | 2024-12-31 | 6,983,000 | USD | 2026-03-30 | 10-K · 0001493152-26-013664 |
| 2023-01-01 | 2023-12-31 | 5,450,000 | USD | 2025-04-15 | 10-K · 0000950170-25-054278 |
| 2022-01-01 | 2022-12-31 | 9,561,000 | USD | 2024-03-29 | 10-K · 0000950170-24-038661 |
| 2021-01-01 | 2021-12-31 | 9,133,455 | USD | 2023-05-01 | 20-F · 0001410578-23-000848 |
| 2020-01-01 | 2020-12-31 | 8,820,204 | USD | 2023-05-01 | 20-F · 0001410578-23-000848 |
| 2019-01-01 | 2019-12-31 | 8,739,420 | USD | 2022-05-16 | 20-F · 0001410578-22-001546 |
| 2018-01-01 | 2018-12-31 | 11,795,376 | USD | 2021-04-21 | 20-F · 0001104659-21-052672 |
| 2017-01-01 | 2017-12-31 | 23,285,279 | USD | 2020-03-31 | 20-F · 0001104659-20-040722 |
| 2016-01-01 | 2016-12-31 | 17,306,001 | USD | 2019-04-23 | 20-F · 0001144204-19-020749 |
| 2015-01-01 | 2015-12-31 | 5,799,076 | USD | 2018-07-18 | 20-F · 0001144204-18-038891 |
| 2014-01-01 | 2014-12-31 | 1,616,204 | USD | 2017-03-31 | 20-F · 0001144204-17-018167 |
| 2013-01-01 | 2013-12-31 | 1,276,000 | USD | 2015-02-11 | 10-K · 0001144204-15-007770 |
| 2012-01-01 | 2012-12-31 | 1,483,000 | USD | 2015-02-11 | 10-K · 0001144204-15-007770 |
| 2011-01-01 | 2011-12-31 | 841,000 | USD | 2014-03-24 | 20-F · 0001144204-14-017308 |
| 2010-01-01 | 2010-12-31 | 247,000 | USD | 2013-04-19 | 20-F/A · 0001144204-13-022773 |
Related financial histories
- Akari Therapeutics, Plc: total assets
- Akari Therapeutics, Plc: total liabilities
- Akari Therapeutics, Plc: stockholders equity
- Akari Therapeutics, Plc: cash and cash equivalents
- Akari Therapeutics, Plc: net income or loss
- Akari Therapeutics, Plc: operating cash flow
- Akari Therapeutics, Plc: capital expenditure payments
- Akari Therapeutics, Plc: financing cash flow
- Akari Therapeutics, Plc: investing cash flow
- Akari Therapeutics, Plc: retained earnings or deficit
- Akari Therapeutics, Plc: basic weighted-average shares
- Akari Therapeutics, Plc: diluted weighted-average shares
- Akari Therapeutics, Plc: basic earnings per share
- Akari Therapeutics, Plc: diluted earnings per share
- Akari Therapeutics, Plc: income tax expense or benefit
- Akari Therapeutics, Plc: net property, plant and equipment
- Akari Therapeutics, Plc: share-based compensation expense
- Akari Therapeutics, Plc: operating income or loss
- Akari Therapeutics, Plc: current assets
- Akari Therapeutics, Plc: interest expense
- Akari Therapeutics, Plc: current liabilities
- Akari Therapeutics, Plc: current accounts payable
- Akari Therapeutics, Plc: goodwill carrying amount
- Akari Therapeutics, Plc: operating expenses
- Akari Therapeutics, Plc: selling, general and administrative expense
Inspect the source
- Entity
- Akari Therapeutics, Plc / CIK 0001541157
- Captured
- 2026-09-20T09:17:38.520Z
- SEC response SHA-256
28aa6200c3956b4742e82320b97671468c61e673338f20b4055d5cab77ff39a0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001541157.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))